🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

The sexually transmitted infection are on the rise around the world, with figures suggesting in excess of 82 million infections per year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the reality of rising global incidence, escalating drug resistance and the very limited available drugs at this time.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program found that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, was also approved in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization represents a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Research Study Results and Worldwide Availability

According to data detailed in a major medical journal, the new drug cured more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which combines a dual-drug approach. The trial involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to license and sell the drug in numerous low-income and middle-income countries.

Clinicians treating patients have shared positive views. The availability of a one-pill regimen such as this is seen as a "critical tool" for managing the epidemic. This is viewed as essential to lessen the impact of the infection for patients and to prevent the spread of extremely resistant gonorrhoea globally.